In previous studies, cyclophilin inhibitors, such as CsA, have exhibited a decrease in proliferation in HCC [27], but the potential use of CsA as a treatment against HCC might be complicated due to its immunosuppressive activity [24]. The gene discussed is PPIB; the disease is hepatocellular carcinoma.